Chest
Original ResearchPulmonary Vascular DiseaseThe REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension
Section snippets
Materials and Methods
A comprehensive description of the design of the REVEAL Registry, including inclusion and exclusion criteria and statistical methods, has been published, as has a description of the 2,716 patients included in the model development cohort and the methods used to develop the predictive survival algorithm.4, 5 Variables independently associated with increased mortality in the multivariable survival model included a collection of etiologic factors and parameters that can be identified by physical
Results
The validation cohort comprised 504 individuals with newly diagnosed PAH who were enrolled between September 2007 and December 2009 and who met the traditional hemodynamic criteria (pulmonary capillary wedge pressure ≤ 15 mm Hg). The characteristics of these patients and of those in the model development cohort are shown in Table 1. At the time of enrollment, the mean age of patients in the validation cohort was 53 years, 74% were women, and 69% were white. Compared with the model development
Discussion
PAH is a comparatively rare condition, which has made it historically difficult to study. For this reason, large registry studies are useful in better defining the condition and for providing insight into factors that influence survival and prognosis. When compared with previous registry studies,8, 9, 10, 11, 12, 13, 14, 15 The REVEAL Registry is the largest and most comprehensive registry to date. Indeed, the size of the validation cohort—the subject of the present analysis—is as large as or
Acknowledgments
Author contributions: Dr Benza: contributed to the study design; collection, analysis, and interpretation of data; and drafting and critical review of the manuscript and has seen and approved the final version.
Dr Gomberg-Maitland: contributed to the study design; collection, analysis, and interpretation of data; and drafting and critical review of the manuscript and has seen and approved the final version.
Mr Miller: contributed to the study design; collection, analysis, and interpretation of
References (22)
- et al.
The changing picture of pulmonary arterial hypertension patients in the United States: how the REVEAL registry differs from historic and non-US contemporary registries
Chest
(2011) - et al.
Design of the REVEAL registry for US patients with pulmonary arterial hypertension
Mayo Clin Proc
(2008) - et al.
Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension
Chest
(2000) - et al.
Temporal trends and drug exposures in pulmonary hypertension: an American experience
Am Heart J
(2006) - et al.
Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension
Chest
(2007) - et al.
Integration of clinical and hemodynamic parameters in the prediction of long-term survival in pulmonary arterial hypertension
Chest
(2011) - et al.
Predicting outcome in coronary disease. Statistical models versus expert clinicians
Am J Med
(1986) - et al.
Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications
Circulation
(2009) - et al.
Current diagnostic and prognostic assessment of pulmonary hypertension
Rev Esp Cardiol
(2010) - et al.
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
Circulation
(2010)
Immortal time bias in observational studies of drug effects
Pharmacoepidemiol Drug Saf
Cited by (415)
Emergencies in Pulmonary Hypertension
2024, Cardiology ClinicsCT-derived lung vessel morphology correlates with prognostic markers in precapillary pulmonary hypertension
2024, Journal of Heart and Lung TransplantationIs low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials
2023, The Lancet Respiratory MedicinePrognostic Stratification and Treatment for Pulmonary Arterial Hypertension. Gaps and Promising Remedies
2023, Archivos de BronconeumologiaPulmonary arterial hypertension
2023, Presse Medicale
Funding/Support: Funding for the REVEAL Registry is provided by Actelion Pharmaceuticals US, Inc.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).